* p = .009
DESCRIPTION
A. CD3 + in patients. CD3 + in patients. CD3 + CD8 + in patients. CD3 + CD4 + in patients. B. C. CD4 + CD25 high CD45RO +. CD4 + CD28 + CD45RO +. * P = .009. * P = .001. *. *. % of CD3 + CD4 + T cells. % of CD3 + CD4 + T cells. Supplementary Figure 1 - PowerPoint PPT PresentationTRANSCRIPT
CD4+CD28+CD45RO+
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Pre-NST day+30 day+60 day+100
% o
f C
D3+
CD
4+ T
cel
ls
Patients Normal controls
C.CD4+CD25highCD45RO+
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
Pre-NST day+30 day+60 day+100
% o
f C
D3+
CD
4+ T
cel
ls
Patients Normal controls
B.
0
200
400
600
800
1000
1200
1400
Pre-NST day+30 day+60 day+100 day+130 day+160
abso
lute
cou
nt /
mm
3
CD3+ in patients CD3+ in normal controls
CD3+CD4+ in patients CD3+CD8+ in patients
A.
*P = .009 *P = .001
*
*
B C
A
Supplementary Figure 1
Immune reconstitution in patients was monitored over the course of transplant. (A) Recovery of CD3+, CD4+ and CD8+ T lymphocytes in patients (n = 20) post-NST. (B) and (C) show two specific CD4+ subsets, each represented as a percentage of the CD4+ compartment, in patients versus healthy normal controls (n = 20). CD4+CD25highCD45RO+ regulatory T cells (B) markedly decreased between pre-NST and day+30, whereas CD4+CD28+CD45RO+ T cells (C) increased between pre-NST and day+30 and maintained consistently higher levels than normal controls throughout (*denotes significant difference at pre-NST between patients and normal controls; NST, nonmyeloablative blood stem cell transplant).
CD4+CD28+CD45RO+CD4+CD25highCD45RO+
% o
f C
D3+
CD
4+ T
ce
lls
% o
f C
D3+
CD
4+ T
ce
lls
CD3+ in patients
CD3+CD4+ in patients
CD3+ in patients
CD3+CD8+ in patients
Supplementary Figure 2
Chimerism trends in the ten responders (seven with partial response, PR and three with stable disease, SD) shown in relation with DLI infusions (indicated by arrows over the graph). The horizontal bar below each graph represents the post-transplantation timeline for the responder showing critical events including onset of regression (indicated by a triangle), removal of cyclosporin (indicated by an oval), and onset of GVHD (indicated by a diamond). Late response timepoints are also shown (“late PR” in patients 7, 16 and 19).
Patient 4
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 6
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 7
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 9
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 13
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 14
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 16
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 18
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 19
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Patient 20
0
20
40
60
80
100
0 28 56 84 112 140 168 196 224 252 280 308 336 364
Days after transplantation
% D
on
or
Ch
imer
ism
Days after transplantation
% D
on
or
Ch
ime
ris
m
Late PR day+662
Late PR day+129
Late PR day+101